Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
DBV Technologies
ISIN FR0010417345
|WKN A1JWB7
Market cap (in EUR)
706 m
Country
France
Sector
Healthcare
Overview
Description
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
Healthcare Biopharmaceuticals Other Biopharmaceuticals France
Financials
Key metrics
| Market capitalisation, EUR | 706 m |
| EPS, EUR | -0.60 |
| P/B ratio | 5.0 |
| P/E ratio | - |
| Dividend yield | - |
Income statement (2025)
| Revenue, EUR | - |
| Net income, EUR | -130 m |
| Profit margin | - |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.